still NO generic pip/tazo

This forum made possible through the generous support of SDN members, donors, and sponsors. Thank you.

StewardshipDude

Full Member
10+ Year Member
Joined
Jun 12, 2009
Messages
70
Reaction score
0
Looks like Wyeth has submitted another citizen's petition based on some new Ron Jones data:

  • 2008 paper by Ronald Jones, MD et al comparing the in vitro potency of Zosyn and various generic forms of pt against several pathogens.
  • 2009 ECCMID poster provided additional data on the same study
  • CONCLUSIONS: An average of 42% decreased potency vs. pseudomonas aeruginosa compared to Zosyn, with a range of from 16%-60%.
All generics were made in India(3) or China (12) home of high quality products.

None of the generics found outside the US are 787 compliant. NONE.

Hmmmmm,.......crickets.....crickets....
 
Looks like Wyeth has submitted another citizen's petition based on some new Ron Jones data:

  • 2008 paper by Ronald Jones, MD et al comparing the in vitro potency of Zosyn and various generic forms of pt against several pathogens.
  • 2009 ECCMID poster provided additional data on the same study
  • CONCLUSIONS: An average of 42% decreased potency vs. pseudomonas aeruginosa compared to Zosyn, with a range of from 16%-60%.
All generics were made in India(3) or China (12) home of high quality products.

None of the generics found outside the US are 787 compliant. NONE.

Hmmmmm,.......crickets.....crickets....
Z? Is this you?
 
Looks like Wyeth has submitted another citizen's petition based on some new Ron Jones data:

  • 2008 paper by Ronald Jones, MD et al comparing the in vitro potency of Zosyn and various generic forms of pt against several pathogens.
  • 2009 ECCMID poster provided additional data on the same study
  • CONCLUSIONS: An average of 42% decreased potency vs. pseudomonas aeruginosa compared to Zosyn, with a range of from 16%-60%.
All generics were made in India(3) or China (12) home of high quality products.

None of the generics found outside the US are 787 compliant. NONE.

Hmmmmm,.......crickets.....crickets....

LOL... the troll is back. So you're going to take a non blinded lab study sponsored by Wyeth in the US as the benchmark?? where do you see the decrease potency of 42%? If you actually look at the MICs..you'll see that it took a very creative calculation to even derive 16% decrease. Look at the table 2... they deemed Orchid brand (marketed with Hospira) to be equivalent... ha...which is the product released in Europe...they also mention even the wyeth brand resulted in variation in MIC. Dood, give it up. By the way...can you post the table 2 for everyone to see?

http://www.jmilabs.com/data/posters/ASM2008\A-079.pdf


Caver and Karm...shame on you two.
 
get the popcorn ready!
 
How do they expect me to compare the generics if the brand is given as a range? If table 2 shows me anything, its that ABX vary from lot and that is about it. The Brand is given as a range and most of the point values for the generics are w/in that range. But I may be wrong as I'm not an ID person
 
Top